Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever
Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
Empirical antibiotic therapy has been known to reduce the mortality and morbidity rate in
neutropenic fever. Until now, ceftazidime was the first line choice of neutropenic fever.
However, resistance against ceftazidime has been reported. Several countries have reported
cefepime in reducing fever and shorten the length of hospitalization better than ceftazidime.
This study is aimed to compare the effectivity of ceftazidime and cefepime to reduce fever
and to increase the absolute neutrophils count (ANC) in the first 72 hours.